<DOC>
	<DOCNO>NCT02876224</DOCNO>
	<brief_summary>This open-label , multicenter , single-arm , two-stage , Phase Ib study design assess safety , tolerability , pharmacokinetics oral cobimetinib intravenous ( IV ) atezolizumab bevacizumab participant metastatic colorectal cancer ( mCRC ) receive progress least one prior line therapy contain fluoropyrimidine oxaliplatin irinotecan . There two stage study : Stage 1 ( safety run-in period ) Stage 2 ( dose expansion two cohort , expansion cohort biopsy cohort ) .</brief_summary>
	<brief_title>Study Cobimetinib Combination With Atezolizumab Bevacizumab Participants With Gastrointestinal Other Tumors</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Eastern Cooperative Oncology Group performance status 0 1 Histologically confirm unresectable metastatic colorectal adenocarcinoma Life expectancy least 12 week Progression prior line therapy contain fluoropyrimidine oxaliplatin irinotecan unresectable metastatic colorectal adenocarcinoma Measurable disease per RECIST v1.1 Adequate hematologic end organ function Creatinine clearance great equal ( &gt; = ) 30 milliliter per minute ( mL/min ) For biopsy cohort , participant must bevacizumab naive receive last bevacizumab treatment least 12 month prior Cycle 1 Day 1 accord investigator 's judgment plan biopsy would expose participant substantially increase risk For woman childbearing potential , agreement remain abstinent ( refrain heterosexual intercourse ) use nonhormonal contraceptive method result failure rate le ( &lt; ) 1 percent ( % ) per year treatment period least 180 day last study treatment . For men , agreement remain abstinent ( refrain heterosexual intercourse ) use 2 contraceptive measure , agreement refrain donate sperm Participants know microsatellite ( MSI ) high status Major surgery significant traumatic injury within 60 day prior enrollment Treatment anticancer agent within 28 day prior Cycle 1 Day 1 Minor surgical procedure within 15 day study Cycle 1 Day 1 Untreated central nervous system ( CNS ) metastases Treatment investigational agent approve therapy within 28 day Malignancies colorectal cancer within 5 year prior Cycle 1 Day 1 Prior radiation therapy within 30 day prior study Cycle 1 Day 1 and/or persistence radiationrelated adverse effect Prior allogeneic bone marrow transplantation solid organ transplant another malignancy past Spinal cord compression definitively treat surgery and/or radiation Uncontrolled pleural effusion , pericardial effusion , ascites require recurrent drainage procedure Current recent use therapeutic oral parenteral anticoagulant thrombolytic agent Intake St. John 's wort hyperforin ( potent cytochrome P450 CYP3A4 enzyme inducer ) grapefruit juice ( potent cytochrome P450 CYP3A4 enzyme inhibitor ) within 7 day prior initiation study treatment History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion protein Known hypersensitivity allergy biopharmaceuticals produce Chinese hamster ovary cell component cobimetinib , atezolizumab , bevacizumab formulation Prior treatment cluster differentiation ( CD ) 137 ( CD137 ) agonists immune checkpoint blockage therapy , antiprogrammed death protein1 , antiprogram deathligand 1 , mitogenactivated protein kinase ( MEK ) inhibitor Human Immunodeficiency Virus ( HIV ) infection Active hepatitis B hepatitis C History autoimmune disease , significant pulmonary disease , significant cardiovascular disease Administration live , attenuate vaccine within 4 week randomization History evidence retinal pathology ophthalmologic examination consider risk factor central serous retinopathy , retinal vein occlusion , neovascular macular degeneration History idiopathic pulmonary fibrosis , organize pneumonia , druginduced pneumonitis , idiopathic pneumonitis Uncontrolled tumor pain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>